Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 55

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 55
---
%                     |     |                           $706,500 |
| Mark S. Verratti                      
 Chief Commercial Officer              |     |    $560,000 |     | 75%                                            |     | 116.6%                     |     |                           $489,720 |
| Dale Muzzey, Ph.D.                    
 Chief Scientific Officer              |     |    $506,400 |     | 50%                                            |     | 104.7%                     |     |                           $265,100 |

(1) Total payout percentage was calculated based on the sum of the revenue, adjusted operating income, engagement score/customer NPS and individual MBO payout percentages. Mr. Diaz's revenue, adjusted operating income, engagement/customer NPS, and individual MBO payout percentages were 43.6%, 45.0%, 5.4%, 6.7%, and 20.0%, respectively. Mr. Leffler's revenue, adjusted operating income, engagement/customer NPS, and individual MBO payout percentages were 38.2%, 37.5%, 5.4%, 6.7%, and 24.9%, respectively. Mr. Leffler's 2024 fiscal year bonus amount was prorated based on the number of days that Mr. Leffler worked during fiscal year 2024. Mr. Raha's revenue, adjusted operating income, engagement/customer NPS, and individual MBO payout percentages were 43.6%, 45.0%, 5%, 6.7%, and 25%, respectively. Mr. Verratti's revenue, adjusted operating income, engagement/customer NPS, and individual MBO payout percentages were 43.6%, 45.0%, 5.4%, 6.7%, and 16.0%, respectively. Dr. Muzzey's revenue, adjusted operating income, engagement/customer NPS, and individual MBO payout percentages were 32.7%, 30.0%, 5.4%, 6.7%, and 30.0%, respectively. 40

Long-Term Incentive Awards For fiscal year 2024 , long-term incentive compensation was granted in the form of 50% RSUs and 50% PSUs. In determining the amount of equity compensation to be awarded, the CHCC considers various factors, including but not limited to: • our financial and operating performance for the applicable period; • the executive officer’s contribution to our performance; • the anticipated